On May 9, 2024, Senti Biosciences, Inc., a biotechnology company specializing in cell and gene therapies, announced its financial results for the first quarter ended March 31, 2024. The company, which is based in South San Francisco, California, and incorporated in Delaware, is listed on the Nasdaq Capital Market under the trading symbol SNTI. Senti Biosciences reported cash and cash equivalents of $23.7 million and an additional $18.9 million in receivables from the GeneFab transaction. Research and development expenses increased to $8.8 million, up from $7.1 million in the same period the previous year, primarily due to manufacturing costs for the company's programs. General and administrative expenses decreased to $7.5 million from $9.2 million, attributed to a reduction in workforce earlier in the year. The net loss for the...Show More

On May 9, 2024, Senti Biosciences, Inc., a biotechnology company specializing in cell and gene therapies, announced its financial results for the first quarter ended March 31, 2024. The company, which is based in South San Francisco, California, and incorporated in Delaware, is listed on the Nasdaq Capital Market under the trading symbol SNTI. Senti Biosciences reported cash and cash equivalents of $23.7 million and an additional $18.9 million in receivables from the GeneFab transaction. Research and development expenses increased to $8.8 million, up from $7.1 million in the same period the previous year, primarily due to manufacturing costs for the company's programs. General and administrative expenses decreased to $7.5 million from $9.2 million, attributed to a reduction in workforce earlier in the year. The net loss for the quarter was $12.1 million, or $0.26 per share. The company also highlighted its pipeline progress, including the upcoming Phase 1 clinical trial of SENTI-202 for acute myeloid leukemia (AML) and a pilot trial of SENTI-301A for hepatocellular carcinoma (HCC) in China through a partnership with Celest. Senti Biosciences also presented new research at the ASGCT 2024 Annual Meeting and announced a strategic collaboration with Celest Therapeutics for clinical development in China. The company's CEO, Timothy Lu, M.D., Ph.D., emphasized Senti Biosciences' commitment to leveraging synthetic biology to address unmet clinical needs.